

# GEORGIAN MEDICAL NEWS

---

ISSN 1512-0112

No 1 (310) Январь 2021

---

ТБИЛИСИ - NEW YORK



ЕЖЕМЕСЯЧНЫЙ НАУЧНЫЙ ЖУРНАЛ

Медицинские новости Грузии  
საქართველოს სამედიცინო სიახლენი

# GEORGIAN MEDICAL NEWS

No 1 (310) 2021

Published in cooperation with and under the patronage  
of the Tbilisi State Medical University

Издается в сотрудничестве и под патронажем  
Тбилисского государственного медицинского университета

გამოიცემა თბილისის სახელმწიფო სამედიცინო უნივერსიტეტთან  
თანამშრომლობითა და მისი პატრონაჟით

ЕЖЕМЕСЯЧНЫЙ НАУЧНЫЙ ЖУРНАЛ  
ТБИЛИСИ - НЬЮ-ЙОРК

**GMN: Georgian Medical News** is peer-reviewed, published monthly journal committed to promoting the science and art of medicine and the betterment of public health, published by the GMN Editorial Board and The International Academy of Sciences, Education, Industry and Arts (U.S.A.) since 1994. **GMN** carries original scientific articles on medicine, biology and pharmacy, which are of experimental, theoretical and practical character; publishes original research, reviews, commentaries, editorials, essays, medical news, and correspondence in English and Russian.

**GMN** is indexed in MEDLINE, SCOPUS, PubMed and VINITI Russian Academy of Sciences. The full text content is available through EBSCO databases.

**GMN: Медицинские новости Грузии** - ежемесячный рецензируемый научный журнал, издаётся Редакционной коллегией и Международной академией наук, образования, искусств и естествознания (IASEIA) США с 1994 года на русском и английском языках в целях поддержки медицинской науки и улучшения здравоохранения. В журнале публикуются оригинальные научные статьи в области медицины, биологии и фармации, статьи обзорного характера, научные сообщения, новости медицины и здравоохранения.

Журнал индексируется в MEDLINE, отражён в базе данных SCOPUS, PubMed и ВИНТИ РАН. Полнотекстовые статьи журнала доступны через БД EBSCO.

**GMN: Georgian Medical News** – საქართველოს სამედიცინო სიახლენი – არის ყოველთვიური სამეცნიერო სამედიცინო რეცენზირებადი ჟურნალი, გამოიცემა 1994 წლიდან, წარმოადგენს სარედაქციო კოლეგიისა და აშშ-ის მეცნიერების, განათლების, ინდუსტრიის, ხელოვნებისა და ბუნებისმეტყველების საერთაშორისო აკადემიის ერთობლივ გამოცემას. GMN-ში რუსულ და ინგლისურ ენებზე ქვეყნდება ექსპერიმენტული, თეორიული და პრაქტიკული ხასიათის ორიგინალური სამეცნიერო სტატიები მედიცინის, ბიოლოგიისა და ფარმაციის სფეროში, მიმოხილვითი ხასიათის სტატიები.

ჟურნალი ინდექსირებულია MEDLINE-ის საერთაშორისო სისტემაში, ასახულია SCOPUS-ის, PubMed-ის და ВИНТИ РАН-ის მონაცემთა ბაზებში. სტატიების სრული ტექსტი ხელმისაწვდომია EBSCO-ს მონაცემთა ბაზებშიდან.

## МЕДИЦИНСКИЕ НОВОСТИ ГРУЗИИ

Ежемесячный совместный грузино-американский научный электронно-печатный журнал  
Агентства медицинской информации Ассоциации деловой прессы Грузии,  
Международной академии наук, индустрии, образования и искусств США.  
Издается с 1994 г., распространяется в СНГ, ЕС и США

### ГЛАВНЫЙ РЕДАКТОР

Николай Пирцхалаишвили

### НАУЧНЫЙ РЕДАКТОР

Елене Гиоргадзе

### ЗАМЕСТИТЕЛЬ ГЛАВНОГО РЕДАКТОРА

Нино Микаберидзе

### НАУЧНО-РЕДАКЦИОННЫЙ СОВЕТ

**Зураб Вадачкориа - председатель Научно-редакционного совета**

Михаил Бахмутский (США), Александр Геннинг (Германия), Амиран Гамкрелидзе (Грузия),  
Константин Кипиани (Грузия), Георгий Камкамидзе (Грузия),  
Паата Куртанидзе (Грузия), Вахтанг Масхулия (Грузия),  
Тенгиз Ризнис (США), Реваз Сепиашвили (Грузия), Дэвид Элуа (США)

### НАУЧНО-РЕДАКЦИОННАЯ КОЛЛЕГИЯ

**Константин Кипиани - председатель Научно-редакционной коллегии**

Архимандрит Адам - Вахтанг Ахаладзе, Амиран Антадзе, Нелли Антелава, Тенгиз Асатиани,  
Гия Берадзе, Рима Бериашвили, Лео Бокерия, Отар Герзмава, Лиана Гогиашвили, Нодар Гогебашвили,  
Николай Гонгадзе, Лия Дваладзе, Тамар Долиашвили, Манана Жвания, Тамар Зерекидзе,  
Ирина Квачадзе, Нана Квирквелия, Зураб Кеванишвили, Гурам Кикнадзе, Димитрий  
Кордзаиа, Теймураз Лежава, Нодар Ломидзе, Джанлуиджи Мелотти, Марина Мамаладзе,  
Караман Пагава, Мамука Пирцхалаишвили, Анна Рехвиашвили, Мака Сологашвили, Рамаз Хецуриани,  
Рудольф Хохенфеллнер, Кахабер Челидзе, Тинатин Чиковани, Арчил Чхотуа,  
Рамаз Шенгелия, Кетеван Эбралидзе

Website:

[www.geomednews.org](http://www.geomednews.org)

The International Academy of Sciences, Education, Industry & Arts. P.O.Box 390177,  
Mountain View, CA, 94039-0177, USA. Tel/Fax: (650) 967-4733

**Версия:** печатная. **Цена:** свободная.

**Условия подписки:** подписка принимается на 6 и 12 месяцев.

**По вопросам подписки обращаться по тел.: 293 66 78.**

**Контактный адрес:** Грузия, 0177, Тбилиси, ул. Асатиани 7, IV этаж, комната 408  
тел.: 995(32) 254 24 91, 5(55) 75 65 99

Fax: +995(32) 253 70 58, e-mail: [ninomikaber@geomednews.com](mailto:ninomikaber@geomednews.com); [nikopir@geomednews.com](mailto:nikopir@geomednews.com)

**По вопросам размещения рекламы обращаться по тел.: 5(99) 97 95 93**

© 2001. Ассоциация деловой прессы Грузии

© 2001. The International Academy of Sciences,  
Education, Industry & Arts (USA)

## **GEORGIAN MEDICAL NEWS**

Monthly Georgia-US joint scientific journal published both in electronic and paper formats of the Agency of Medical Information of the Georgian Association of Business Press; International Academy of Sciences, Education, Industry and Arts (USA).  
Published since 1994. Distributed in NIS, EU and USA.

### **EDITOR IN CHIEF**

Nicholas Pirtskhalaishvili

### **SCIENTIFIC EDITOR**

Elene Giorgadze

### **DEPUTY CHIEF EDITOR**

Nino Mikaberidze

### **SCIENTIFIC EDITORIAL COUNCIL**

#### **Zurab Vadachkoria - Head of Editorial council**

Michael Bakhmutsky (USA), Alexander Gënning (Germany),  
Amiran Gamkrelidze (Georgia), David Elua (USA),  
Konstantin Kipiani (Georgia), Giorgi Kamkamidze (Georgia), Paata Kurtanidze (Georgia),  
Vakhtang Maskhulia (Georgia), Tengiz Riznis (USA), Revaz Sepiashvili (Georgia)

### **SCIENTIFIC EDITORIAL BOARD**

#### **Konstantin Kipiani - Head of Editorial board**

Archimandrite Adam - Vakhtang Akhaladze, Amiran Antadze, Nelly Antelava,  
Tengiz Asatiani, Gia Beradze, Rima Beriashvili, Leo Bokeria, Kakhaber Chelidze,  
Tinatin Chikovani, Archil Chkhotua, Lia Dvaladze, Tamar Doliashvili, Ketevan Ebralidze,  
Otar Gerzmava, Liana Gogiashvili, Nodar Gogebashvili, Nicholas Gongadze,  
Rudolf Hohenfellner, Zurab Kevanishvili, Ramaz Khetsuriani, Guram Kiknadze,  
Dimitri Kordzaia, Irina Kvachadze, Nana Kvirkvelia, Teymuraz Lezhava, Nodar Lomidze, Marina  
Mamaladze, Gianluigi Melotti, Kharaman Pagava, Mamuka Pirtskhalaishvili,  
Anna Rekhviashvili, Maka Sologhashvili, Ramaz Shengelia, Tamar Zerekidze, Manana Zhvania

### **CONTACT ADDRESS IN TBILISI**

GMN Editorial Board  
7 Asatiani Street, 4<sup>th</sup> Floor  
Tbilisi, Georgia 0177

Phone: 995 (32) 254-24-91  
995 (32) 253-70-58  
Fax: 995 (32) 253-70-58

### **CONTACT ADDRESS IN NEW YORK**

NINITEX INTERNATIONAL, INC.  
3 PINE DRIVE SOUTH  
ROSLYN, NY 11576 U.S.A.

Phone: +1 (917) 327-7732

### **WEBSITE**

[www.geomednews.org](http://www.geomednews.org)

## К СВЕДЕНИЮ АВТОРОВ!

При направлении статьи в редакцию необходимо соблюдать следующие правила:

1. Статья должна быть представлена в двух экземплярах, на русском или английском языках, напечатанная через **полтора интервала на одной стороне стандартного листа с шириной левого поля в три сантиметра**. Используемый компьютерный шрифт для текста на русском и английском языках - **Times New Roman (Кириллица)**, для текста на грузинском языке следует использовать **AcadNusx**. Размер шрифта - **12**. К рукописи, напечатанной на компьютере, должен быть приложен CD со статьей.

2. Размер статьи должен быть не менее десяти и не более двадцати страниц машинописи, включая указатель литературы и резюме на английском, русском и грузинском языках.

3. В статье должны быть освещены актуальность данного материала, методы и результаты исследования и их обсуждение.

При представлении в печать научных экспериментальных работ авторы должны указывать вид и количество экспериментальных животных, применявшиеся методы обезболивания и усыпления (в ходе острых опытов).

4. К статье должны быть приложены краткое (на полстраницы) резюме на английском, русском и грузинском языках (включающее следующие разделы: цель исследования, материал и методы, результаты и заключение) и список ключевых слов (key words).

5. Таблицы необходимо представлять в печатной форме. Фотокопии не принимаются. **Все цифровые, итоговые и процентные данные в таблицах должны соответствовать таковым в тексте статьи**. Таблицы и графики должны быть озаглавлены.

6. Фотографии должны быть контрастными, фотокопии с рентгенограмм - в позитивном изображении. Рисунки, чертежи и диаграммы следует озаглавить, пронумеровать и вставить в соответствующее место текста **в tiff формате**.

В подписях к микрофотографиям следует указывать степень увеличения через окуляр или объектив и метод окраски или импрегнации срезов.

7. Фамилии отечественных авторов приводятся в оригинальной транскрипции.

8. При оформлении и направлении статей в журнал МНГ просим авторов соблюдать правила, изложенные в «Единых требованиях к рукописям, представляемым в биомедицинские журналы», принятых Международным комитетом редакторов медицинских журналов - <http://www.spinesurgery.ru/files/publish.pdf> и [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html) В конце каждой оригинальной статьи приводится библиографический список. В список литературы включаются все материалы, на которые имеются ссылки в тексте. Список составляется в алфавитном порядке и нумеруется. Литературный источник приводится на языке оригинала. В списке литературы сначала приводятся работы, написанные знаками грузинского алфавита, затем кириллицей и латиницей. Ссылки на цитируемые работы в тексте статьи даются в квадратных скобках в виде номера, соответствующего номеру данной работы в списке литературы. Большинство цитированных источников должны быть за последние 5-7 лет.

9. Для получения права на публикацию статья должна иметь от руководителя работы или учреждения визу и сопроводительное отношение, написанные или напечатанные на бланке и заверенные подписью и печатью.

10. В конце статьи должны быть подписи всех авторов, полностью приведены их фамилии, имена и отчества, указаны служебный и домашний номера телефонов и адреса или иные координаты. Количество авторов (соавторов) не должно превышать пяти человек.

11. Редакция оставляет за собой право сокращать и исправлять статьи. Корректур авторам не высылаются, вся работа и сверка проводится по авторскому оригиналу.

12. Недопустимо направление в редакцию работ, представленных к печати в иных издательствах или опубликованных в других изданиях.

**При нарушении указанных правил статьи не рассматриваются.**

## REQUIREMENTS

Please note, materials submitted to the Editorial Office Staff are supposed to meet the following requirements:

1. Articles must be provided with a double copy, in English or Russian languages and typed or computer-printed on a single side of standard typing paper, with the left margin of 3 centimeters width, and 1.5 spacing between the lines, typeface - **Times New Roman (Cyrillic)**, print size - 12 (referring to Georgian and Russian materials). With computer-printed texts please enclose a CD carrying the same file titled with Latin symbols.

2. Size of the article, including index and resume in English, Russian and Georgian languages must be at least 10 pages and not exceed the limit of 20 pages of typed or computer-printed text.

3. Submitted material must include a coverage of a topical subject, research methods, results, and review.

Authors of the scientific-research works must indicate the number of experimental biological species drawn in, list the employed methods of anesthetization and soporific means used during acute tests.

4. Articles must have a short (half page) abstract in English, Russian and Georgian (including the following sections: aim of study, material and methods, results and conclusions) and a list of key words.

5. Tables must be presented in an original typed or computer-printed form, instead of a photocopied version. **Numbers, totals, percentile data on the tables must coincide with those in the texts of the articles.** Tables and graphs must be headed.

6. Photographs are required to be contrasted and must be submitted with doubles. Please number each photograph with a pencil on its back, indicate author's name, title of the article (short version), and mark out its top and bottom parts. Drawings must be accurate, drafts and diagrams drawn in Indian ink (or black ink). Photocopies of the X-ray photographs must be presented in a positive image in **tiff format**.

Accurately numbered subtitles for each illustration must be listed on a separate sheet of paper. In the subtitles for the microphotographs please indicate the ocular and objective lens magnification power, method of coloring or impregnation of the microscopic sections (preparations).

7. Please indicate last names, first and middle initials of the native authors, present names and initials of the foreign authors in the transcription of the original language, enclose in parenthesis corresponding number under which the author is listed in the reference materials.

8. Please follow guidance offered to authors by The International Committee of Medical Journal Editors guidance in its Uniform Requirements for Manuscripts Submitted to Biomedical Journals publication available online at: [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)  
[http://www.icmje.org/urm\\_full.pdf](http://www.icmje.org/urm_full.pdf)

In GMN style for each work cited in the text, a bibliographic reference is given, and this is located at the end of the article under the title "References". All references cited in the text must be listed. The list of references should be arranged alphabetically and then numbered. References are numbered in the text [numbers in square brackets] and in the reference list and numbers are repeated throughout the text as needed. The bibliographic description is given in the language of publication (citations in Georgian script are followed by Cyrillic and Latin).

9. To obtain the rights of publication articles must be accompanied by a visa from the project instructor or the establishment, where the work has been performed, and a reference letter, both written or typed on a special signed form, certified by a stamp or a seal.

10. Articles must be signed by all of the authors at the end, and they must be provided with a list of full names, office and home phone numbers and addresses or other non-office locations where the authors could be reached. The number of the authors (co-authors) must not exceed the limit of 5 people.

11. Editorial Staff reserves the rights to cut down in size and correct the articles. Proof-sheets are not sent out to the authors. The entire editorial and collation work is performed according to the author's original text.

12. Sending in the works that have already been assigned to the press by other Editorial Staffs or have been printed by other publishers is not permissible.

**Articles that Fail to Meet the Aforementioned  
Requirements are not Assigned to be Reviewed.**



## ავტორთა საქურაღებოლ!

რედაქციაში სტატიის წარმოდგენისას საჭიროა დაიცვათ შემდეგი წესები:

1. სტატია უნდა წარმოადგინოთ 2 ცალად, რუსულ ან ინგლისურ ენებზე დაბეჭდილი სტანდარტული ფურცლის 1 გვერდზე, 3 სმ სიგანის მარცხენა ველისა და სტრიქონებს შორის 1,5 ინტერვალის დაცვით. გამოყენებული კომპიუტერული შრიფტი რუსულ და ინგლისურენოვან ტექსტებში - **Times New Roman (Кириллица)**, ხოლო ქართულენოვან ტექსტში საჭიროა გამოვიყენოთ **AcadNusx**. შრიფტის ზომა – 12. სტატიას თან უნდა ახლდეს CD სტატიით.

2. სტატიის მოცულობა არ უნდა შეადგენდეს 10 გვერდზე ნაკლებს და 20 გვერდზე მეტს ლიტერატურის სიის და რეზიუმეების (ინგლისურ, რუსულ და ქართულ ენებზე) ჩათვლით.

3. სტატიაში საჭიროა გაშუქდეს: საკითხის აქტუალობა; კვლევის მიზანი; საკვლევი მასალა და გამოყენებული მეთოდები; მიღებული შედეგები და მათი განსჯა. ექსპერიმენტული ხასიათის სტატიების წარმოდგენისას ავტორებმა უნდა მიუთითონ საექსპერიმენტო ცხოველების სახეობა და რაოდენობა; გაუტკივარებისა და დაძინების მეთოდები (მწვავე ცდების პირობებში).

4. სტატიას თან უნდა ახლდეს რეზიუმე ინგლისურ, რუსულ და ქართულ ენებზე არანაკლებ ნახევარი გვერდის მოცულობისა (სათაურის, ავტორების, დაწესებულების მითითებით და უნდა შეიცავდეს შემდეგ განყოფილებებს: მიზანი, მასალა და მეთოდები, შედეგები და დასკვნები; ტექსტუალური ნაწილი არ უნდა იყოს 15 სტრიქონზე ნაკლები) და საკვანძო სიტყვების ჩამონათვალი (key words).

5. ცხრილები საჭიროა წარმოადგინოთ ნაბეჭდი სახით. ყველა ციფრული, შემაჯამებელი და პროცენტული მონაცემები უნდა შეესაბამებოდეს ტექსტში მოყვანილს.

6. ფოტოსურათები უნდა იყოს კონტრასტული; სურათები, ნახაზები, დიაგრამები - დასათაურებული, დანომრილი და სათანადო ადგილას ჩასმული. რენტგენოგრაფიების ფოტოასლები წარმოადგინეთ პოზიტიური გამოსახულებით **tiff** ფორმატში. მიკროფოტოსურათების წარწერებში საჭიროა მიუთითოთ ოკულარის ან ობიექტივის საშუალებით გადიდების ხარისხი, ანათალების შედეგის ან იმპრეგნაციის მეთოდი და აღნიშნოთ სურათის ზედა და ქვედა ნაწილები.

7. სამამულო ავტორების გვარები სტატიაში აღინიშნება ინიციალების თანდართვით, უცხოურისა – უცხოური ტრანსკრიპციით.

8. სტატიას თან უნდა ახლდეს ავტორის მიერ გამოყენებული სამამულო და უცხოური შრომების ბიბლიოგრაფიული სია (ბოლო 5-8 წლის სიღრმით). ანბანური წყობით წარმოდგენილ ბიბლიოგრაფიულ სიაში მიუთითეთ ჯერ სამამულო, შემდეგ უცხოელი ავტორები (გვარი, ინიციალები, სტატიის სათაური, ჟურნალის დასახელება, გამოცემის ადგილი, წელი, ჟურნალის №, პირველი და ბოლო გვერდები). მონოგრაფიის შემთხვევაში მიუთითეთ გამოცემის წელი, ადგილი და გვერდების საერთო რაოდენობა. ტექსტში კვადრატულ ფხიხლებში უნდა მიუთითოთ ავტორის შესაბამისი N ლიტერატურის სიის მიხედვით. მიზანშეწონილია, რომ ციტირებული წყაროების უმეტესი ნაწილი იყოს 5-6 წლის სიღრმის.

9. სტატიას თან უნდა ახლდეს: ა) დაწესებულების ან სამეცნიერო ხელმძღვანელის წარდგინება, დამოწმებული ხელმოწერითა და ბეჭდით; ბ) დარგის სპეციალისტის დამოწმებული რეცენზია, რომელშიც მითითებული იქნება საკითხის აქტუალობა, მასალის საკმაობა, მეთოდის სანდოობა, შედეგების სამეცნიერო-პრაქტიკული მნიშვნელობა.

10. სტატიის ბოლოს საჭიროა ყველა ავტორის ხელმოწერა, რომელთა რაოდენობა არ უნდა აღემატებოდეს 5-ს.

11. რედაქცია იტოვებს უფლებას შეასწოროს სტატია. ტექსტზე მუშაობა და შეჯერება ხდება საავტორო ორიგინალის მიხედვით.

12. დაუშვებელია რედაქციაში ისეთი სტატიის წარდგენა, რომელიც დასაბეჭდად წარდგენილი იყო სხვა რედაქციაში ან გამოქვეყნებული იყო სხვა გამოცემებში.

აღნიშნული წესების დარღვევის შემთხვევაში სტატიები არ განიხილება.



Содержание:

<b>Taner Demirci, Hasret Cengiz, Sedat Cetin, Seyhun Varim, Gizem Karatas Kılıçcıoğlu</b> MYELOLIPOMA COEXISTENCE WITH GLUCOCORTICOID AND ANDROGEN SECRETING ADRENOCORTICAL CARCINOMA: SLOW AND BENIGN CLINICAL COURSE.....	7
<b>Русин В.И., Русин В.В., Горленко Ф.В., Добош В.М., Лопит М.М.</b> ИЗОЛИРОВАННАЯ ПРОФУНДОПЛАСТИКА (ДИФФЕРЕНЦИРОВАННЫЙ ВЫБОР).....	11
<b>Зубач О.Б., Григорьева Н.В., Поворозник В.В.</b> 10-ЛЕТНЯЯ ЛЕТАЛЬНОСТЬ У ПАЦИЕНТОВ ПОСЛЕ ПЕРЕЛОМОВ ПРОКСИМАЛЬНОГО ОТДЕЛА БЕДРЕННОЙ КОСТИ.....	19
<b>Zenaishvili M., Japaridze Sh., Tushishvili A., Davitashvili O., Kevanishvili Z.</b> STUTTERING: INITIATING FACTORS, EVOLUTION, HEALING PERSPECTIVES.....	23
<b>Hirna H., Kostyshyn I., Rozhko M., Levandovskyi R., Nakashidze G.</b> ANALYSIS OF IMMUNE CHANGES AND THEIR ROLE IN THE DEVELOPMENT OF ORAL AND OROPHARYNGEAL CANCER .....	29
<b>Tsitadze T., Puturidze S., Lomidze T., Margvelashvili V., Kalandadze M.</b> PREVALENCE AND RISK-FACTORS OF BRUXISM IN CHILDREN AND ADOLESCENT POPULATION AND ITS IMPACT ON QUALITY OF LIFE (REVIEW).....	36
<b>Solovyeva Z., Zaporozhskaya-Abramova E., Adamchik A., Gushchin A., Risovanniy S., Manukyan I.</b> COMPARATIVE EVALUATION OF THE CLINICAL EFFICACY OF MODERN REMINERALIZING DRUGS IN THE TREATMENT OF ENAMEL CARIES (FOCAL DEMINERALIZATION) .....	39
<b>Bakradze A., Vadachkoria Z., Kvachadze I.</b> ELECTROPHYSIOLOGICAL CORRELATES OF MASTICATORY MUSCLES IN NASAL AND ORONASAL BREATHING MODES .....	45
<b>Borysenko A., Timokhina T., Kononova O.</b> INDICATORS OF LOCAL IMMUNITY IN THE COMORBID COURSE OF CARIES AND GASTROESOPHAGEAL REFLUX DISEASE.....	48
<b>Dolidze K., Margvelashvili V., Nikolaishvili M., Suladze T., Pkhaladze M.</b> STUDY OF THE HYGIENIC CHARACTERISTICS OF THE ORAL CAVITY UNDER THE COMPLEX EFFECT OF PHOTODYNAMIC THERAPY AND TSKALTUBO SPRING WATER RADON HORMESIS.....	54
<b>Танская О.А., Островский Ю.П., Курлянская Е.К., Валентюкевич А.В., Колядко М.Г.</b> ОСНОВНЫЕ КРИТЕРИИ ОТБОРА ПАЦИЕНТОВ ПРИ ФОРМИРОВАНИИ ЛИСТА ОЖИДАНИЯ НА ТРАНСПЛАНТАЦИЮ СЕРДЦА .....	60
<b>Yelshibayeva E., Dautov T., Rakhimzhanova R., Gutberlet M., Mardenkyzy D., Kozhakhmetova Zh., Saduakasova A.</b> COMPUTED TOMOGRAPHY IN DETECTING FEATURES OF CORONARY ATHEROSCLEROSIS IN DIFFERENT ETHNIC GROUPS OF KAZAKHSTAN POPULATION.....	68
<b>Podzolkov V., Safronova T., Nebieridze N., Loriya I., Cherepanov A.</b> TRANSFORMING GROWTH FACTOR AND ARTERIAL STIFFNESS IN PATIENTS WITH UNCONTROLLED ARTERIAL HYPERTENSION .....	77
<b>Gvasalia T., Kvachadze I., Giorgobiani T.</b> SENSITIVITY TO MECHANICAL PAIN BASED ON SATIETY LEVELS IN WOMEN .....	83
<b>Povoroznyuk V., Nishkumay O., Lazarieva K., Lazariyev P.</b> FEATURES OF BONE METABOLISM AND THEIR INFLUENCE ON ARTERIAL WALL STIFFNESS IN POSTMENOPAUSAL WOMEN WITH CONTROLLED UNCOMPLICATED HYPERTENSION .....	87
<b>Solomonina N., Vacharadze K., Mgvdeladze G.</b> CHARACTERISTICS OF DRUG RESISTANT TUBERCULOSIS IN GEORGIA (2015-2020).....	93

<b>Abramidze T., Gotua M., Bochorishvili E., Melikidze N., Gamkrelidze A.</b> CYPRESS POLLEN SENSITIZATION IN GEORGIA: CLINICAL AND MOLECULAR CHARACTERISTICS.....	101
<b>Притыко Н.Г., Коваленко О.Е.</b> ОСОБЕННОСТИ МОЗГОВОЙ ГЕМОДИНАМИКИ У ПАЦИЕНТОВ С СИНДРОМОМ ХРОНИЧЕСКОЙ ЦЕРЕБРАЛЬНОЙ ВЕНОЗНОЙ ДИСФУНКЦИИ И РАЗНЫМ УРОВНЕМ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ.....	107
<b>Chorna V., Makhniuk V., Pshuk N., Gumeniuk N., Shevchuk Yu., Khliestova S.</b> BURNOUT IN MENTAL HEALTH PROFESSIONALS AND THE MEASURES TO PREVENT IT .....	113
<b>Ratiani L., Gegechkory S., Machavariani K., Shotadze T., Sanikidze T., Intskirveli N.</b> THE PECULIARITY OF COVID-19 GENOME AND THE CORONAVIRUS RNA TRANSLATION PROCESS AS A POTENTIAL TARGET FOR ETIOTROPIC MEDICATIONS WITH ADENINE AND OTHER NUCLEOTIDE ANALOGUES (REVIEW).....	119
<b>Patarashvili L., Azmaipharashvili E., Jandieri K., Gvidiani S., Tsomaia K., Kikalishvili L., Sareli M., Chanukvadze I., Kordzaia D.</b> LIVER EXTRACELLULAR MATRIX PECULIARITIES IN MAMMALS AND AVIANS.....	124
<b>Tsomaia K., Azmaipharashvili E., Gvidiani S., Bebiashvili I., Gusev S., Kordzaia D.</b> STRUCTURAL CHANGES IN RATS' LIVER DURING THE FIRST 2 WEEKS FOLLOWING 2/3 PARTIAL HEPATECTOMY .....	134
<b>Gvianishvili T., Kakauridze N., Gogiashvili L., Tsagareli Z., Kurtanidze T.</b> CORRELATION OF THYROID AUTOIMMUNITY WITH ATHEROSCLEROSIS EVALUATION IN HASHIMOTO'S THYROIDITIS.....	142
<b>Kiknadze T., Tevdorashvili G., Muzashvili T., Gachechiladze M., Burkadze G.</b> PHENOTYPIC CHARACTERISTICS OF RELAPSED LEIOMYOMA AND SMOOTH MUSCLE TUMORS OF UNCERTAIN MALIGNANCY POTENTIAL IN REPRODUCTIVE WOMEN.....	150
<b>Pkhakadze G., Bokhua Z., Asatiani T., Muzashvili T., Burkadze G.</b> STEM CELL INDEX IN THE PROGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA.....	157
<b>Pidlisetsky A., Savosko S., Dolhopolov O., Makarenko O.</b> PERIPHERAL NERVE LESIONS AFTER A MECHANICALLY INDUCED LIMB ISCHEMIA.....	165
<b>Kolisnyk I., Voloshin O., Savchenko I., Yanchevskiy O., Rashidi B.</b> ENZYMATIC ACTIVITY IN MICROSOMES, LIPID PEROXIDATION OF MICE HEPATOCYTES UNDER THE SODIUM FLUORIDE.....	169
<b>Smagulova A., Katokhin A., Mambetpayeva B., Kulmaganbetova N., Kiyan V.</b> A MULTIPLEX PCR ASSAY FOR THE DIFFERENTIAL DETECTION OF OPISTHORCHIS FELINEUS AND METORCHIS BILIS .....	176
<b>Rigvava S., Karumidze N., Kusradze I., Dvalidze T., Tatrishvili N., Goderdzishvili M.</b> BIOLOGICAL CHARACTERIZATION OF BACTERIOPHAGES AGAINST STREPTOCOCCUS AGALACTIAE .....	182
<b>Deshko L., Udovenko Zh., Bulycheva N., Galagan V., Bulychev A.</b> PROVISION OF THE RIGHT TO NON-INTERFERENCE WITH PRIVACY DURING MUSTER PROCESS WITH THE PARTICIPATION OF DOCTOR (FORENSIC EXPERT) .....	186
<b>Теремецкий В.И., Николаенко Т.Н., Дидковская Г.В., Гмырин А.А., Шаповал Т.Б.</b> КОНТРОЛЬ И НАДЗОР КАК СРЕДСТВА ПРЕДУПРЕЖДЕНИЯ И ВЫЯВЛЕНИЯ ПРАВОНАРУШЕНИЙ В СФЕРЕ ЗДРАВООХРАНЕНИЯ.....	192

## CORRELATION OF THYROID AUTOIMMUNITY WITH ATHEROSCLEROSIS EVALUATION IN HASHIMOTO'S THYROIDITIS

<sup>1</sup>Gvianishvili T., <sup>2</sup>Kakauridze N., <sup>1</sup>Gogiashvili L., <sup>1</sup>Tsagareli Z., <sup>2</sup>Kurtanidze T.

<sup>1</sup>Ivane Javakhishvili Tbilisi State University, Alexandre Natishvili Institute of Morphology;  
<sup>2</sup>Tbilisi State Medical University, Georgia

According to clinical and scientific research results, the thyroid gland dysfunction (hypothyroidism) plays a significant role in the development of dyslipidemia, atherosclerosis (At) and hence the coronary heart disease (CHD) pathogenesis.

Accumulating results of numerous cross-sectional epidemiological investigations indicate that among other important risk factors, the hypothyroidism and high serum TSH levels are more pronounced causes of endothelial dysfunction, histomorphological changes of large vessels' wall and impact on the mechanisms of cholesterol metabolism. McLeod 2013 [1], based on the large meta-analysis study [2], suggested a causal relationship between autoimmune thyroid disease and atherosclerosis [3-5].

By 2019 ESC/EAS Guideline [6], except of the traditional risk factors, such as the dyslipidemia - high level of Total cholesterol (TC), low density lipoprotein cholesterol (LDLC), triglycerides and low level of high density lipoprotein cholesterol (HDL) - noted the high importance of carotid and femoral intima-media thickness (IMT) for presence of atherosclerosis in patients with CHD and subclinical hypothyroidism (SH) [7-12].

The study region - Georgia (South Caucasus) is an iodine-deficient area with a high prevalence of iodine-deficiency-related disease, such as endemic goiter, thyroid nodules, Hashimoto thyroiditis (HT) - most common cause of primary hypothyroidism [1, 13-15]. Due to the substantial changes in lipid metabolism, these conditions increase high-risk morphological features of atherosclerosis [16, 17]. Against this background, hypercholesterolemia has a direct relationship and the impacts on the dynamics of histomorphological changes in the Hashimoto's thyroid parenchyma; there are significant debates regarding the aim on which the present study is mainly concentrated.

Recently, the relationship between subclinical hypothyroidism (SH) and cardiovascular diseases has been one of the most popular topics. There is still some controversy concerning the cardiovascular impact of SH and management protocols.

The aim of the present study is to investigate the putative association between Hashimoto thyroiditis parenchyma changes and At cardiovascular disease (CHD) clinical characteristics focusing on the causal connection between thyroid function indexes, the lipid profile with follicular epithelium's molecular biology details.

**Material and methods.** We investigated the patients in Georgian National Center of Internal Medicine and Tbilisi State University affiliated Hospitals (Departments of cardiology, surgery and pathology). Present study was reviewed and deemed exempt from written informed consent by the Ethics committee and Board of medical sciences at Tbilisi State University based on Helsinki-ethical principles declaration for medical research [18].

To reach the planned goal we investigated 52 patients (female), which had undergone total thyroidectomy, lobectomy. In the research basic groups (I and II) were included the patients (pts) with Hashimoto thyroiditis (HT) - 28 pts, and HT with atherosclerosis - 24 pts. For underlining the significance of HT in atherosclerosis patients with atherosclerosis (without HT) - 27 pts were included in control (group III).

The diagnosis of atherosclerosis were established by 2019 ESC/EAS criteria - confirmed ACVD (CHD, carotid and femoral arteries atherosclerosis) by using ECG, echocardiography, stress tests, carotid and femoral arteries ultrasonography and in some cases coronarography. The diagnosis of HT were established by TSH, FT4, FT3, anti-TPO tests and confirmed in postoperative specimens histology.

The exclusion criteria were: the patients having III-IV functional class (by Canadian Cardiovascular Society grading of angina pectoris) and unstable angina pectoris, heart failure III-IV (by NYHA classification), arterial hypertension grade 1, 2, 3 (by ESC/ESH guideline, 2018) [19], diabetes mellitus, hepatic and renal failure.

For all studying patients the following analysis was provided: lipid profile, TSH, FT4, Anti TPO; carotid, femoral, thyroid gland ultrasonography.

### Laboratory tests

#### Thyroid hormones and anti TPO

Subclinical hypothyroidism (SH) is characterized by normal serum free T<sub>4</sub> and free T<sub>3</sub> levels and increased serum TSH levels.

Patients involved in the study underwent TSH by the enzyme-linked immunosorbent assay (ELISA) methods name "SANDWICH"-96, well plate, source-serum, venous blood, plasma, IU/ml 0-35 IU/ml, free thyroxine testing, and antibody titer to thyroid peroxidase [20].

Thyroid markers reference range: TSH 0.3-4.2 mIU/L, FT4 0.9-1.7 ng/dL, Anti-TPO <9.0 IU/mL, Anti-Tg <4.0 IU/mL [21, 22].

Thyroid disease categorization and thyroid function index - TSH and FT4 respectively:

Subclinical hypothyroidism > 4.2 mIU/L and 0.9-1.7 ng/dL

Subclinical hyperthyroidism < 0.3 mIU/L and 0.9-1.7 ng/dL

Overt hypothyroidism > 4.2 mIU/L and < 0.9 ng/dL

Overt hyperthyroidism < 0.3 mIU/L and > 1.7 ng/dL

#### Lipids profile:

Blood samples were taken after 13 hour fasting. Lipid spectrum was studied in blood serum using "Janway" spectrometry. The quantitative determination of total cholesterol (TC) was performed triglycerides (TG) were determined by the enzyme method, while the content of high density lipoprotein-cholesterol (HDL): low density lipoprotein - cholesterol (LDLC) and very low density lipoprotein - cholesterol (VLDLC) were determined after the precipitation of low density lipoprotein -cholesterol using BIOLABO, France reactive. LDLC were calculated by Friedwald. The main criteria were: total cholesterol (TC) > 160mg/dl, low density lipoprotein - cholesterol (LDLC) > 100mg/dl, high density lipoprotein - cholesterol (HDL) 150mg/dl.

### Ultrasound diagnostically methods

#### Echocardiography

LV mass (LVM) calculations have been made using linear measurements derived from 2D targeted M-mode. LVM estimated by the ASE-recommended formula (from LV linear dimensions):  $LVM = 0.8 \{1.04[(LVIDd + PWTd + SWTd)^3 - (LVIDd)^3]\} + 0.6$  g where PWTd and SWTd are posterior wall thickness at end diastole and septal wall thickness at end diasto-

le, respectively. LVIDd (LV internal diastolic dimension. The indexation of LVM (g/m<sup>2</sup>) determined in accordance with Height (m) and Body surface area (BSA) m<sup>2</sup>.

#### Carotid and femoral arteries ultrasonography

Carotid and femoral arteries intima-media thicknesses were investigated by high-resolution ultrasonography on sonoscope TOSHIBA-SSH 140-A by 5 MHz and 7, 5 MHz linear transducers. The degree of carotid stenosis was determined in transversal and longitudinal sections. The intima-media complexes and atherosclerotic plaques height was measured by the triplex scanning method. Carotid arteries intima-media thickness (IMT) was defined from bifurcation 20 mm proximally and 30 mm distally [23]. IMT normal value is <1 mm.

#### Ultrasonography of the thyroid gland

Ultrasonographic examinations were performed on a TOSHIBA SSH-140-A scanner with 5, 7, and 3.5 MHz transmissions. Examination of the thyroid gland used B to assess the thickness, width, length, and size of the thyroid gland using the appropriate formula (thickness × width × length × 0.479) to assess the structure, surface condition, diffuse and focal changes.

#### Histological examination

All patients provided written informed consents. This study protocol was approved by the ethics committee of medical sciences at Tbilisi State University based on Helsinki-ethical principles declaration for medical research [18]. The research database included postoperative surgical pathology material obtained from patients with thyroiditis who had undergone total thyroidectomy, lobectomy, and partial resection of the thyroid gland. The pathology material was received from Surgical Units of Tbilisi and West Georgia National Center of Interventional Medicine. Both retrospective data (for the years 2014) as well as prospective material (for the years 2018-2019) were analyzed. Basically, thyroidectomies in the I and II groups of patients were performed for the following reasons: a. patients with bilateral or multiple nodules or symptoms of neck or throat compression, or enlargement during follow-up and b. clinical and physical data indicated for removal.

The diagnosis of HT was based on the level in serum anti peroxidase level - 186 (63-438), TSH, FT4 range and histological findings.

For histological examination of thyroid operative materials, the sliced sections were stained with routine Hematoxylin and Eosin (H&E). Formalin-fixed paraffin embedded (FFPE) tissue sections were routinely processed and stained with hematoxylin and eosin. Immunohistochemical (IHC) staining was performed on FFPE tissue sections with antibodies against the following markers: 1. S100 Protein (clone RTU-S100p Polyclone Antibodies, Biogenex, USA), because Hürthle cells reaction is most remarkable in HT disorders; and 2. p63 (clone 7JUL, Leica, UK), which is a p53 gene family at 3q27-29 homologue nuclear transcription factor. Three of p63 isoforms encode proteins that transactivate on p53 activity and induct cell into apoptosis. The other three isoforms encode proteins, which have inhibitory effect on p53 activity [24]; in our cases, p63 is important to detect oxyphilic metaplasia of thyroid follicular epithelium. As positive control Palatine Tonsils lymphoid tissue specimens were used.

FFPE sections were fixed on poly-L-lysine-coated glass slides and prepared as follows: 1) deparaffinization, rehydration and incubation for 20 minutes in 3% H<sub>2</sub>O<sub>2</sub>; 2) Immersion in phosphate-buffered saline (PBS) for 20 min; 3) Antigen retrieval in the microwave (600 W) for 20 min, followed by cooling in citrate buffer (0.01 m, pH 6.0). Specimens were incubated with

the primary antibodies for 1 hour at room temperature. After that was washed three times with PBS at room temperature. Hematoxylin is used for nuclei counterstaining. All procedures were carried out in compliance with antibodies manufacturers' protocols (Bio Genex, USA; Leica, UK).

Histology slides were reviewed by two pathologists (L. G., T. G.). We used the 2015 American Thyroid Association management guidelines [21, 22].

The statistical analysis was performed using Microsoft Excel 7.0, SPSS-20 version and Mann-Whitney U-test. M±SD (M-mean SD-standard deviation) was calculated. Student-t test was used for the analysis of the data obtained for the groups, Fisher's F criterion for comparing dispersions Differences were considered statistically significant when "p" value was less than 5% (p < 0.05). Correlation was tested according to the Pearson's correlation. Comparisons between groups and factors were made using Multivariable linear regression and analysis to evaluate independent risk factors (TSH, IMT, demographic variables (age and gender)) [3, 5, 7]. The coefficient of reliability was calculated by t-s statistics for two different averages and F-statistics. The results of the study were recorded in tables and diagrams.

**Results and discussion.** The confidence of our results is based on the following points:

1. The study groups do not differ by age, BMI or numbers of patients, which excludes influences in the comparison of Lipid spectrum, TSH and FT4 levels.
2. The clinical characters similarity of the study groups of HT+At (group II) and At (group III) permits to underline the TSH responsibility on the development of dyslipidemia (Fig. 1).




Fig. 1. Clinical characteristic of patients in group II (AT+HT) and group III (At)

The clinical characters of the group III (AT) vs group II (AT+HT) are presented in Figure 1. By the analyses of the diagrams 1 and 2 there is no significant differences of group II vs group III patients clinical characteristics that describe the severity of At (Hypertension -16 % vs 18%; stable angina 37% vs 39%; HF 12% vs 13%; post- Myocardial Infarction (MI) 28% vs 28%; carotid artery At, except of femoral artery At - 53% vs 66%.

Analysis of the thyroid gland's functional tests - TSH and FT4, revealed statistically significant differences (P<0.001) between Anti-TPO negative group III (patients with At) (TSH:1.2±0.3mIU/L; FT4: 1.2±0.3 ng/dl) and Anti-TPO positive two groups: group I (patients with HT) (TSH:6.0±1.6mIU/L; FT4: 0.98±0.15 ng/dl) and group II (patients with HT+At) (TSH:5.80±1.7mIU/L). There was not thyroid gland's functional tests any differences between group I and II patients as we don't reveal statistical reliable differences of FT4 (P2-3 >0.2) level between group II patients (FT4: 1.1±0.2 ng/dl) and group III patients (FT4: 1.2±0.3 ng/dl) (Table 1).

Table 1. Summary of Baseline Characteristics for Patients With HT, HT+At and At

Groups		Age	BMI	TSH	FT4	TC	LDLC	HDLC	TG
HT (I)	M	62.8	27.4	6	0.98	246.2	172.1	49.3	123.9
	StD	1.2	1.2	1.6	0.15	25.5	23.3	6.1	26.2
HT+At(II)	M	64.6	27.6	5.8	1.1	276.6	204.1	41.3	155.8
	StD	3.8	1	1.7	0.2	11.7	14	6.5	23.6
AT (III)	M	63.0	27.1	1.2	1.2	211.1	139.4	42.9	150.0
	StD	3.0	1.0	0.3	0.3	29.6	29.7	5.0	22.9
				TSH	FT4	TC	LDLC	HDLC	TG
			p1-2	0.3	0.2	0.001	0.001	0.001	0.001
			p1-3	0.001	0.001	0.001	0.001	0.001	0.0002
			p2-3	0.001	0.2	0.001	0.001	0.001	0.001

HT- Hashimoto Thyroiditis; At-atherosclerosis; BMI (kg/m<sup>2</sup>)- Body mass index, TC (mg/dl) –Total Cholesterol; LDLC (mg/dl) –Low density Lipoprotein Cholesterol; HDLC (mg/dl) – High density Lipoprotein Cholesterol; Triglycerides (mg/dl); TSH – (mIU/L; FT4 (ng/dL); Anti-TPO (IU/mL)




Fig. 2. The characteristics of lipid profile, BMI, TSH, FT4, FA and CA in the study groups

Table 2. CA and FA IMT in study groups

Atherosclerosis		HT(I)	HT+AT(II)	At (III)		
CA (mm)	M	1.04	1.19	1.1	p1-2	0.001
	SD	0.09	0.1	0.11	p1-3	0.03
					p2-3	0.0004
FA (mm)	M	1.29	1.47	1.18	p1-2	0.001
	SD	0.13	0.2	0.12	p1-3	0.002
					p2-3	0.0001

Lipid spectre demonstrates more atherogenic changes in II group (HT+At) patients (TC 276,6±11.7.5 mg/dl; LDLC 204,1± 14.0mg/dl; TG 155.8±23.6mg/dl; HDL 41.3±6.5 mg/dl), than in patients with At, but without HT (group III) (TC 211.1±29.6 mg/dl; LDLC 139.4±29.7mg/dl; TG 123.9± 22.9 mg/dl; HDL 49.3± 6.1 mg/dl).

TSH and anti-TPO are important in the development of atherosclerosis as indicated by correlation with atherogenic lipid levels (TC 246, 2±25.5 mg/dl; LDLC 211.1± 29.7mg/dl; TG 150.0 ± 22.9 mg/dl; HDL 42.9 ±5.0 mg/dl), increasing in patients with HT (group I). However, in II group (HT+At) LDLC

276.6± 11.7 mg/dl; TG 155.8 ± 23.6mg/dl; HDL 41.3 ±6.5 mg/dl demonstrate elevation of the same data according to a linear relationship between thyroid function index and lipid profile (Tab.1), respecting BMI and age factors.

The CA (carotid artery) intima-media complex thickening is more expressed in group II patients (1,19±0,1 mm) and statistically significantly differs (p2-3<0.0004) as from group II patients indices (1,1±0,11 mm) as from group I patients indices (1,04±0,09 mm). Also, the statistical reliable between group I and group III indices (p1-3<0.03) were observed (Fig. 2).



There were statistically reliable differences between group II patients FA (femoral artery) intima-media complex indicator ( $1,47 \pm 0,2$  mm) with group III atherosclerotic patients without HT ( $1,18 \pm 0,12$  mm)  $p_{2-3} < 0,0001$  and group I patients with HT ( $1,29 \pm 0,13$  mm)  $p_{1-3} < 0,0001$  as well between group I patients with group III patients ( $p < 0,001$ ) (Fig. 2, Table 2).

These results are derived from linear regression data between serum TSH levels and key diagnostic parameters confirming atherosclerosis, where a linear correlation trend was observed between TSH, on the one hand, and FA and CA intima-media thickness, on the other. For intergroup comparison it's likely that the Pearson coefficient showed an active direct correlation with group II, namely, between TSH, LDLC and CA wall thickness ratios. Thus, the latter is one of the most reliable criteria for comparison between groups (Fig. 3).




Fig. 3. Pearson correlation ( $r$ ) between: a - TSH and TC in patients with HT and HT+At (group I and II); b - TSH and LDLC in patients with HT and HT+At (group I and II); c - TSH and FA in patients with HT and HT+At (group I and group II)

We can conclude that TSH, as the main thyroid function regulator, may be determined as principal risk-factor, which independently affects the thyroid morphology as well as carotid and femoral arteries IMT.

#### Baseline characteristics and Histology of Thyroid parenchyma

In generally, the histopathological diagnosis of HT was based on the presence of diffuse, chronic, inflammatory cells infiltrate, mainly composed of T-lymphocytes and plasma cells and macrophage, organized in germinal centers, also fibrotic areas presents, which did not extend beyond the capsule. The infiltrate had to occur in a normal region of the thyroid gland, as well as the presence of atrophic follicles with numerous Hürthle cells and enlarged thyroid cells, characterized by abundant cytoplasm, which was eosinophilic.

Group I (HT) - results of histopathological research of

Hashimoto's thyroiditis causing subclinical hypothyroidism is associated with activity of parallel immunohistochemical reactions, indicating that the thyroid parenchyma is non-homogeneous in terms of parenchyma cell components, as well as molecular biological features. Hashimoto's thyroiditis leading histopathological process is the extensive lymphocytic infiltration of thyroid parenchyma (Fig. 4a), which is accompanied by hypertrophy/hyperplasia of lymphoid follicles and germinal centers, with the abundance of plasma cells and macrophages. In the thyroid parenchyma necrosis areas were not detected.

The high nuclear expression of the protein S100 in HT parenchyma indicates on the dysplasia of the thyroid parenchyma and disorganization of the architecture. Expression of high-intensity S100 protein is associated with Hashimoto's infiltrative foci in the domain between follicles (Fig. 4b).




Fig. 4. HT. a. H&E. Atrophic follicles in the thyroid parenchyma, invasive lymphoid follicles with large germination center; X200. b. S100-protein expression is manifested in the domain between follicles in abundant Hürthle cells. Immunoperoxidase reaction, X160

Group II (HT+atherosclerosis) - In the material of the given group marked the typical histological features of Hashimoto's thyroiditis include moderate lymphoplasmacytic infiltration, follicular destruction following with variable degrees of fibrosis (Fig. 5a).

It is significant, that HT with atherosclerosis association characterised by independent line of Hürthle cells and their






Fig. 5. HT. a. H&E, X100. b. Association of Hürthle cells adenoma and Hashimoto's Thyroiditis. Intense expression of S100 protein on the periphery of the adenoma and in the adenoma capsule, X160. c. Follicular epithelial squamous metaplasia with intense nuclear positive p63 immunostaining, X400; (in rectangle area – control reaction with lymphoid tissue from Palatine Tonsils, X200); Immunoperoxidase reaction

adenoma like hyperplasia, reducing follicular parenchyma, which decrease secretory activity, in fact, hypothyroidism reinforce (Fig. 5b).

In group II (HT+atherosclerosis), new morphological fact develops in some areas of thyroid parenchyma as oxyphilic metaplasia of follicular cells indicating on the severe molecular biological transformation of thyroid parenchyma due to higher low-density lipoprotein cholesterol concentration than in group I (Fig. 5c). Patient from this group also displayed greater CIMT than controls (Fig. 3a, b).

Atherosclerosis and CVD events reduction is very important goal of modern medical society. That is why, beside of the traditional risk factors (dyslipidemia, obesity, hypertension, etc.), scientists attention is focused on the research of the new factors, such as metabolic risk factors and hypothyroidism among them. Taking account the numerous studies about immunological pathogenesis of atherosclerosis [25,26] the importance of Hashimoto thyroiditis influence on CVD events is evident. By 2019 ESC/EAS Guideline [6], next to coronarography, Doppler ultrasound method of carotid and femoral arteries atherosclerotic changes is accepted for confirmation of ACVD.

Based on the above considerations, we examined patients who were operated on due to Hashimoto thyroiditis indications: group I patients HT without atherosclerosis clinical manifestation and group II patients with HT+Atherosclerosis and group III – Atherosclerosis as in control version.

To pick out the importance of atherosclerosis risk factors (dyslipidemia) in the development of atherosclerosis we com-

pared this data with markers of atherosclerosis using carotid and femoral arteries Doppler ultrasonography. This comparison allows immunological factors (anti-TPO) pathologic mechanism influence in patients with HT with atherosclerosis risk-factors. Data of HT+At group's patients vs group's III Atherosclerosis patients accentuate immunological factor (anti-TPO) action on the dyslipidemia that can promote further severity of the atherosclerosis. This point of view is supported by the results of immunohistochemical study of the p63 protein: It was during the combination of atherosclerosis and Hashimoto that foci of p63 expression of squamous epithelial dysplasia were detected (Fig. 5C).

The major risk factors of atherosclerosis – TC, LDLC, TG high and HDLC low levels relation with anti TPO, TSH and FT4 revealed lipid parameters statistically high level in the group II patients but despite high levels of atherogenic lipids, the same status was statistically low in group III (patients with atherosclerosis but without HT) in comparison with group II as well as in group I patients. This fact confirms hypothyroidism with anti TPO importance in processing of atherosclerosis and HT as atherogenic risk factors significance the correlation under anti-TPO between TSH and TC. LDLC in the I ( $r = 0.89^{**}$ ,  $0.81^{**}$ ) and II groups' patients confirmed the immunological status influences in the development of atherosclerosis.

Thus the influence of thyroid hormones on CVD is in conclusive [27]. FT4 levels in middle-aged person are positively associated with At, independently caused cardiovascular risk factors [4,28-31]. In turn, At adversely affected on the lipid cholesterol

and carbohydrates rates metabolism, accelerating hypothyroidism with follicular epithelial meta- and dysplasia manifested in our study by: 1. Hurtle cells activity – adenomatous transformation, 2. follicular cell, oxyphilic metaplasia and focal dysplasia (p63 positivity) [14,17,32]. It's important that in euthyroid individual there was no significant difference between compared date [24, 33].

We suppose, that thyroid hormone plays an important role in the pathogenesis of atherosclerosis and cardiovascular complication through multifunctional physiological effects – such intranuclear genomic and extranuclear nongenomic influences: [26, 34] 1. thyroid hormone acts on the vascular smooth muscles cells, modified endothelial function developing systemic vascular resistance [2,4,33,35,36] and diastolic blood pressure instability [21,33]; 2. Thyroid hormone also reduced LDL and decrease LDL receptor activity [26, 37, 38].

It's well known, that the dyslipidemia and the diastolic hypertension predispose the hypothyroidism in HT and At combination group to accelerate carotid artery IMT. Respectively, our results are in good agreement with this opinion [37, 38].

In the current study we found that free T4 is associated with the severity of atherosclerosis clinical characteristics, but we also found, that TSH and anti-TPO antibody levels are directly and closely linked to the cardiovascular complications (Myocardial infarctions and hypertension).

Furthermore, as discussed above, biomarkers S100 and p63 data results demonstrate negative feedback effects of hypercholesterolemia on the high morphological risk features in Hashimoto parenchyma, which may partially explain the significant trend and pathobiological link of Hashimoto Thyroiditis association with Papillary thyroid carcinoma [13,14,24,25].

Doppler ultrasonography investigation data, revealing CA and FA atherosclerosis and TSH influence, show the presence: 1. FA is most important location for developments of IM complex thickening in HT (group I) and HT+At (group II) confirmed by presence of reliable differences ( $p < 0.001$ ) between II and III groups as between the I and III groups patients. 2. CA thickening characterised all three groups' patients, but more expressed in the group II patients. 3. TSH levels clarify the atherogenic quality by presence of correlation between TSH and FA atherosclerosis ( $r = 0.62^*$ ) as between TSH and CA atherosclerosis ( $r = 0.6^*$  in the group I patients). Anti atherogenic HDLC level, statistically reliable, is highest in the group I patients in comparison to II and III groups' patients that can explain absence of clinical manifestation of atherosclerosis despite of the thickening of CA and FA.

**Conclusion.** Comparative analysis of key phenomena of HT and Atherosclerosis features show that free T4 is associated with the severity of atherosclerosis clinical characteristics, that TSH and anti-TPO antibody levels are directly and closely linked to the cardiovascular complications (Myocardial infarctions and hypertension). Dyslipidemia and the diastolic hypertension accelerate the hypothyroidism in HT and At combination group to predispose carotid artery IMT. Biomarkers S100 and p63 data results demonstrate negative feedback effects of hypercholesterolemia on the high morphological risk features in Hashimoto parenchyma, which may be partially explain the significant trend and pathobiological link of Hashimoto Thyroiditis with Papillary thyroid carcinoma.

Data, presented in the study, will serve as a reference for further investigation.

**Acknowledgments.** This work was supported by the Research Program of Ivane Javakishvili Tbilisi State University and Tbilisi State Medical University.

## REFERENCES

1. McLeod D.S. Autoimmune thyroid disease: a novel risk factor for atherosclerosis? // *Endocrine* 2013; 44:8-10. DOI 10.1007/s12020-013-9952-8.
2. Lozano R., Naghavi M., Foreman K., et al.. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. // *Lancet*. 2012; 380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.
3. Ittermann T., Lorbeer R., Dörr M., et al. High levels of thyroid-stimulating hormone are associated with aortic wall thickness in the general population. // *Eur Radiol*. 2016; 26(12):4490-4496. doi: 10.1007/s00330-016-4316-4.
4. Zaki S.M., Youssef M.F. Thyroid hormone dysfunctions affect the structure of rat thoracic aorta: a histological and morphometric study. // *Folia Morphol (Warsz)*. 2013; 72(4):333-9. doi: 10.5603/fm.2013.0056.
5. Ittermann I., Khattak R.M., Nauck M., Cordova C.M., Völzke H. Shift of the TSH reference range with improved iodine supply in Northeast Germany. // *Eur J Endocrinol*. 2015; 172(3):261-7. doi: 10.1530/EJE-14-0898.
6. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). // *European Heart Journal*, 2020; 41 (1):111–188.
7. Völzke H., Robinson D.M., Schminke U., et al. Thyroid Function and Carotid Wall Thickness. // *The Journal of Clinical Endocrinology & Metabolism*, 2004; 89(5):2145–2149, doi: org/10.1210/jc.2003-031028
8. Dullaart R.P., Vries R., Roozendaal C., Kobold A.C., Sluiter W.J. Carotid artery intima media thickness is inversely related to serum free thyroxine in euthyroid subjects. // *Clin Endocrinol (Oxf)*. 2007; 67(5):668-73. doi: 10.1111/j.1365-2265.2007.02943.x.
9. Hak A.E., Pols H.A., Visser T.J., Drexhage H.A., Hofman A., Witteman J.C. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. // *Ann Intern Med*. 2000; 132(4):270-8. doi: 10.7326/0003-4819-132-4-200002150-00004.
10. Takamura N., Akilzhanova A., Hayashida N., et al. Thyroid function is associated with carotid intima-media thickness in euthyroid subjects. // *Atherosclerosis*. 2009; 204(2):e77-81. doi: 10.1016/j.atherosclerosis.2008.09.022.
11. Moulakakis K.G., Sokolis D.P., Perrea D.N., et al. The mechanical performance and histomorphological structure of the descending aorta in hyperthyroidism. // *Angiology*, 2007; 58(3):343-352. DOI: 10.1177/0003319707301759.
12. Völzke H., Robinson D.M., Spielhagen T., et al. Are serum thyrotropin levels within the reference range associated with endothelial function? // *Eur Heart J*. 2009; 30(2):217-24. doi: 10.1093/eurheartj/ehn508.
13. Rurua N., Gogiashvili L., Tsagareli Z. Immunohistochemical investigation of angiogenesis activity in thyroid gland under Hashimoto's Thyroiditis versus Diffuse Toxic Goiter. // *Journal of Basic & Clinical Medicine* 2015; 4(1):32-36.

14. Gvianishvili T., Gogiashvili L., Chkhobadze M. Molecular-biological thyroid profile during autoimmune disease - Hashimoto and Riedel's Thyroiditis. // Georgian Medical News, 2019; №5 (290):116-120.
15. Tsagareli Z., Gogiashvili L., Nikobadze E., Dgebuadze M., Kvachadze T. Expression of the growth factors in the goitertransformed thyroid gland: correlation with the electronmicroscopic characteristics. // Georgian Medical News, 2011; №9 (198):33-39.
16. Boswijk E., Sanders K.J., Broeders E.P., et al. TSH suppression aggravates arterial inflammation - an <sup>18</sup>F-FDG PET study in thyroid carcinoma patients. // Eur J Nucl Med Mol Imaging. 2019; 46(7):1428-1438. doi: 10.1007/s00259-019-04292-w.
17. Figueroa A.L., Subramanian S.S., Cury R.C., et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. // Circ Cardiovasc Imaging. 2012; 5(1):69-77. doi: 10.1161/CIRCIMAGING.110.959478.
18. WMA DECLARATION OF HELSINKI – ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS. 2013.
19. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). // European Heart Journal, 2018; 39(33):3021–3104, doi.org/10.1093/eurheartj/ehy339
20. MyBioSource.com. <https://www.mybiosource.com/human-elisa-kits/tsh/2504599>
21. Human TSH (Thyroid Stimulating Hormone) ELISA Kit, Catalog No: MBS2504599
22. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. // Thyroid. 2009; 19(11):1167-214. doi: 10.1089/thy.2009.0110.
23. Haugen B.R., Alexander E.K., Bible K.C., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. // Thyroid. 2016; 26(1): 1–133. doi: 10.1089/thy.2015.0020
24. Held C., Hjerdahl P., Eriksson S.V., Björkander I., Forslund L., Rehnqvist N. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. // Eur Heart J. 2001; 22(1):62-72. doi: 10.1053/ehj.1999.2006.
25. Jeong J.Y., Jung J.H., Park J.Y. Expression and diagnostic availability of p63 and CD56 in papillary thyroid carcinoma. // Int J Clin Exp Path. 2016;9(7):7402-10 www.ijcep.com / ISSN:1936-2625/IJCEP0014077
26. Subhi O., Schulten H.-J., Bagatian N., et al. Genetic relationship between Hashimoto's thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto's thyroiditis. // Plos one, 2020; doi.org/10.1371/journal.pone.0234566
27. Ling Y., Jiang J., Gui M., et al. Thyroid Function, Prevalent Coronary Heart Disease, and Severity of Coronary Atherosclerosis in Patients Undergoing Coronary Angiography. // International Journal of Endocrinology. 2015. doi.org/10.1155/2015/708272
28. Bano A., Chaker L., Mattace-Raso F.U., et al. Thyroid Function and the Risk of Atherosclerotic Cardiovascular Morbidity and Mortality: The Rotterdam Study. // Circ Res. 2017; 121(12):1392-1400. doi: 10.1161/CIRCRESAHA.117.311603.
29. Pasqualetti G., Tognini S., Polini A., Caraccio N., Monzani F. Is subclinical hypothyroidism a cardiovascular risk factor in the elderly? // J Clin Endocrinol Metab. 2013; 98(6):2256-66.
30. Perrotta C., Buldorini M., Assi E., et al. The thyroid hormone triiodothyronine controls macrophage maturation and functions: protective role during inflammation. // Am J Pathol. 2014; 184(1):230-47. doi: 10.1016/j.ajpath.2013.10.006.
31. Cappola A.R., Ladenson P.W. Hypothyroidism and atherosclerosis. // J Clin Endocrinol Metab. 2003; 88(6):2438-44. doi: 10.1210/jc.2003-030398.
32. Rodondi N., Elzen W.P., Bauer D.C., et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. // JAMA. 2010; 304(12):1365-74. doi: 10.1001/jama.2010.1361.
33. Unger P., Ewart M., Wang B.Y., Gan L., Kohtz D.S., Bursteinj D.e. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? // Hum Pathol. 2003; 34(8):764-9. doi: 10.1016/s0046-8177(03)00239-9.
34. Cikim A.S., Oflaz H., Ozbey N., et al. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. // Thyroid. 2004; 14(8):605-9.
35. Rainville, J.R., Weiss, G.L., Evanson, N., Herman, J.P., Vasudevan, N., Tasker, J.G. Membrane-initiated nuclear trafficking of the glucocorticoid receptor in hypothalamic neurons. // Steroids, 2019; (142):55-64. ISSN 0039-128X doi: doi.org/10.1016/j.steroids.2017.12.005
36. Razvi S., Bhana S., Mrabeti S. Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction. // J Thyroid Res. 2019; 22; 4106816. doi: 10.1155/2019/4106816.
37. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. // Circulation. 2016; 133(4):e38-360.
38. Shavdatuashvili T., Kakauridze N., Tsiskarishvili D. Carotid and femoral arteries IM complex changes in subclinical hypothyreosis in postmenopausal women. // Cardiology and Internal medicine.2006. N1. 50-53
39. Shavdatuashvili T., Kipshidze N., Kakauridze N. The peculiarities of atherosclerosis in patients with subclinical hypothyreosis. // Allergy and Immunology. 2006.V.7, №5.563:566

## SUMMARY

### CORRELATION OF THYROID AUTOIMMUNITY WITH ATHEROSCLEROSIS EVALUATION IN HASHIMOTO'S THYROIDITIS

<sup>1</sup>Gvianishvili T., <sup>2</sup>Kakauridze N., <sup>1</sup>Gogiashvili L., <sup>1</sup>Tsagareli Z., <sup>2</sup>Kurtanidze T.

<sup>1</sup>Ivane Javakhishvili Tbilisi State University, Alexandre Natishvili Institute of Morphology;  
<sup>2</sup>Tbilisi State Medical University, Georgia

The relationship between subclinical hypothyroidism (SH) and Atherosclerotic (At) cardiovascular diseases (CVD) has

been one of the most popular topics but causal connection between Hashimoto thyroiditis (HT), lipid profile and follicular



epithelial molecular biology is controversial. We investigated 3 groups of patients (group I – HT, group II - HT+At, group III - At). All laboratory tests for thyroid function and lipid profile detection were used according to international guideline recommendations, coronary and femoral arteries intima-media thickness (IMT) were tested by high-resolution ultrasonography, thyroid gland histology and immunohistochemistry carried out by p63 and S100 protein expression control. The statistical analysis was performed using Microsoft Excel 7.0, SPSS-20 version, Mann–Whitney U–test and Pearson’s correlation. Comparisons between groups and factors were made using Multiple Linear

Regression model. With the results obtained, dyslipidemia and the diastolic hypertension accelerate the hypothyroidism in HT+At group to predispose carotid and femoral arteries IMT. TSH and anti-TPO antibody levels are directly linked to the cardiovascular complications. Biomarkers S100 and p63 data show negative feedback effects of hypercholesterolemia on the high morphological risk features in Hashimoto parenchyma, which may partially explain the significant trend and pathobiological link of HT with Papillary thyroid carcinoma.

**Keywords:** Hashimoto Thyroiditis; Atherosclerosis; Thyroid; p63, S100 immunohistochemistry; Carotid, Femoral IMT.

## РЕЗЮМЕ

### КОРРЕЛЯЦИЯ МЕЖДУ АУТОИММУННЫМ ТИРОИДИТОМ И РАЗВИТИЕМ АТЕРОСКЛЕРОЗА ПРИ ТИРОИДИТЕ ХАШИМОТО

Гвინიაшвили Т.П., Какауридзе Н.Г., Гогиашвили Л.Е., Цагарели З.Г., Куртанидзе Т.И.

*Тбилисский государственный университет им. И. Джавахишвили, Институт морфологии им. А.Н. Натишвили;  
Тбилисский государственный медицинский университет, Грузия*

Изучение взаимосвязи между субклиническим гипотиреозом и атеросклерозом сердечно-сосудистой системы (At) представляется актуальным, однако причинно-следственная корреляция между тиреоидитом Хашимото (HT), липидным профилем и молекулярной биологией фолликулярного эпителия щитовидной железы по сей день остается малоизученной.

Исследованы 3 группы пациентов: I группа – HT, II группа – HT+At, III группа – At. Используются лабораторные тесты с целью определения функции щитовидной железы и липидного профиля, согласно указаниям международных гайдлайнов. Толщину интимы-медии сонных и бедренных артерий (IMT) оценивали высокоразрешенной ультразвуковой графикой. Материал исследовали гистологическими и имму-

ногистохимическими методами: H&E, S100 протеин и p63.

Статистический анализ проводили по версии Microsoft Excel 7.0, SPSS 20, Mann-Whitney. Использовали U-тест и коэффициент корреляции Пирсона. Сравнительный межгрупповой анализ проводили методом линейной регрессии.

Согласно полученным результатам, дислипидемия и диастолическая гипертензия способствуют прогрессии гипотиреоза в группе HT+At; уровень TSH и anti-TPO антител находится в прямой зависимости от осложнений сердечно-сосудистых заболеваний. S100 и p63 биомаркеры указывают на обратный отрицательный эффект гиперхолестеринемии, на показатели высокого морфологического риска в паренхиме Хашимото, что частично объясняет тенденцию HT и патобиологическую связь с папиллярной карциномой.

## რეზიუმე

ფარისებრი ჯირკვლის აუტომუნურობის კორელაცია ათეროსკლეროზის განვითარებასთან პაშიმოტოს თიროიდიტის დროს

<sup>1</sup>თ.გვინიაშვილი, <sup>2</sup>ნ.კაკაურიძე, <sup>1</sup>ლ.გოგიაშვილი, <sup>1</sup>ზ.ცაგარელი, <sup>2</sup>თ.კურტანიძე

<sup>1</sup>ი.ჯავახიშვილის სახ. თბილისის სახელმწიფო უნივერსიტეტი, ალექსანდრე ნათიშვილის მორფოლოგიის ინსტიტუტი; <sup>2</sup>თბილისის სახელმწიფო სამედიცინო უნივერსიტეტი

სუბკლინიკური ჰიპოთირეოზისა და გულ-სისხლძარღვთა ათეროსკლეროზული (At) დაავადებების ურთიერთკავშირი ერთ-ერთი აქტუალური თემაა, მაგრამ სადავოა პაშიმოტოს თიროიდიტს (HT), ლიპიდურ პროფილსა და ფოლიკულური ეპითელიუმის მოლეკულურ ბიოლოგიას შორის მიზეზობრივი კავშირი. გამოკვლეულია პაციენტების 3 ჯგუფი (I ჯგუფი - HT, II ჯგუფი - HT+At, III ჯგუფი - At). ფარისებრი ჯირკვლის ფუნქციისა და ლიპიდური პროფილის განსაზღვრისთვის გამოყენებული იყო ლაბორატორიული ტესტები საერთაშორისო გაიდლაინების მიითებების შესაბამისად, კორონარული და ბარძაყის არტერიების ინტიმა-მედიის სისქე (IMT) შემოწმდა მაღალი რეზოლუციის ულტრასონოგრაფიით, მასალა შესწავლილია კლასიკური ჰისტოლოგიური და იმუნოჰისტოქიმიური კვლევის მეთოდებით: H&E, S100 ცილა და p63-ის იმუნური პროფილის გათვალისწინებით. სტატისტი-

კური ანალიზი ჩატარდა Microsoft Excel 7.0, SPSS-20 ვერსიის, Mann-Whitney U-ტესტისა და პირსონის კორელაციის გამოყენებით. ჯგუფებსა და ფაქტორებს შორის შედარება განხორციელდა ხაზოვანი რეგრესიის მოდელის გამოყენებით. მიღებული შედეგების მიხედვით, დისლიპიდემია და დიასტოლური ჰიპერტენზია აჩქარებს ჰიპოთირეოზის განვითარებას HT+At ჯგუფში. TSH და anti-TPO ანტისხეულების დონე პირდაპირკავშირშია გულ-სისხლძარღვთა დაავადებების გართულებასთან. S100 და p63 ბიომარკერების მონაცემები აჩვენებს ჰიპერქოლესტერინემიის უარყოფით გავლენას პაშიმოტოს პარენქიმაში მაღალი მორფოლოგიური რისკის მახასიათებლებზე, რითაც ნაწილობრივ შეიძლება აიხსნას პაშიმოტოს მნიშვნელოვანი ტენდენცია და პათობიოლოგიური კავშირი ფარისებრი ჯირკვლის პაპილარული კარცინომასთან.